OncoGenex Pharmaceuticals, Inc. 4,165,000 Shares Common Stock ($0.001 par value) Underwriting AgreementUnderwriting Agreement • March 16th, 2012 • Oncogenex Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances • New York
OncoGenex Pharmaceuticals, Inc., a Delaware corporation (the “Company”) confirms its agreement with Leerink Swann LLC (“Leerink Swann”), Stifel, Nicolaus & Company, Incorporated (“Stifel”) and each of the other Underwriters named in Schedule I hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 12 hereof), for whom Leerink Swann and Stifel are acting as representatives (in such capacity, the “Representatives”), with respect to (i) the issue and sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of 4,165,000 shares of common stock, par value $0.001 per share, of the Company (“Common Stock”), in the respective numbers of shares set forth in said Schedule I, and (ii) the grant by the Company to the Underwriters, severally and not jointly, of the option described in Section 2 hereof to purchase all or any part of up to 624,750 additional shares of Common Stock to cove
